Aptinyx Sees Path Forward In DPN With Long-Term Patients

 
• By Joseph Haas

After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.

Neuropathy that is the damage of peripheral nerves that causes pain and loss of sensation in the extremities.
Neuropathy is damage of peripheral nerves that causes pain and loss of sensation in the extremities

More from Clinical Trials

More from R&D